REFERENCES:
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J
Clin. 2015;65(1):5-29.
- Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A.
Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87-108.
- Oser MG, Niederst MJ, Sequist LV, Engelman JA. Transformation from
non-small-cell lung cancer to small-cell lung cancer: molecular
drivers and cells of origin. Lancet Oncol. 2015;16(4):e165-72.
- Testa U, Castelli G, Pelosi E. Lung Cancers: Molecular
Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem
Cells. Cancers (Basel). 2018;10(8).
- Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell
lung cancer: epidemiology, risk factors, treatment, and survivorship.
Mayo Clin Proc. 2008;83(5):584-94.
- Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current
therapies and new targeted treatments. Lancet.
2017;389(10066):299-311.
- Zugazagoitia J, Guedes C, Ponce S, Ferrer I, Molina-Pinelo S, Paz-Ares
L. Current Challenges in Cancer Treatment. Clin Ther.
2016;38(7):1551-66.
- Herbst RS, Morgensztern D, Boshoff C. The biology and management of
non-small cell lung cancer. Nature. 2018;553(7689):446-54.
- Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin
evaluation: a pooled analysis by the LACE Collaborative Group. J Clin
Oncol. 2008;26(21):3552-9.
10. Kris MG, Gaspar LE, Chaft JE, et al. Adjuvant Systemic Therapy and
Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected
Non-Small-Cell Lung Cancers: American Society of Clinical
Oncology/Cancer Care Ontario Clinical Practice Guideline Update. J Clin
Oncol. 2017;35(25):2960-74.
11. Lu Z, Zou J, Li S, et al. Epigenetic therapy inhibits metastases by
disrupting premetastatic niches. Nature. 2020;579(7798):284-90.
12. Iams WT, Porter J, Horn L. Immunotherapeutic approaches for
small-cell lung cancer. Nat Rev Clin Oncol. 2020;17(5):300-12.
13. Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 Blockade in
Resectable Lung Cancer. N Engl J Med. 2018;378(21):1976-86.
14. Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced
non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines
for diagnosis, treatment and follow-up. Ann Oncol. 2017;28 Suppl
4:iv1-iv21.
15. Tian X, Shen H, Li Z, Wang T, Wang S. Tumor-derived exosomes,
myeloid-derived suppressor cells, and tumor microenvironment. J Hematol
Oncol. 2019;12(1):84.
16. Deng Z, Rong Y, Teng Y, et al. Exosomes miR-126a released from MDSC
induced by DOX treatment promotes lung metastasis. Oncogene.
2017;36(5):639-51.
17. Bremnes RM, Busund LT, Kilvaer TL, et al. The Role of
Tumor-Infiltrating Lymphocytes in Development, Progression, and
Prognosis of Non-Small Cell Lung Cancer. J Thorac Oncol.
2016;11(6):789-800.
18. Caetano MS, Zhang H, Cumpian AM, et al. IL6 Blockade Reprograms the
Lung Tumor Microenvironment to Limit the Development and Progression of
K-ras-Mutant Lung Cancer. Cancer Res. 2016;76(11):3189-99.
19. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as
regulators of the immune system. Nat Rev Immunol. 2009;9(3):162-74.
20. Tian X, Ma J, Wang T, et al. Long non-coding RNA RUNXOR accelerates
MDSC-mediated immunosuppression in lung cancer. BMC cancer.
2018;18(1):660.
21. Tian X, Ma J, Wang T, et al. Long Non-Coding RNA HOXA Transcript
Antisense RNA Myeloid-Specific 1-HOXA1 Axis Downregulates the
Immunosuppressive Activity of Myeloid-Derived Suppressor Cells in Lung
Cancer. Front Immunol. 2018;9:473.
22. Tian J, Rui K, Tang X, et al. MicroRNA-9 Regulates the
Differentiation and Function of Myeloid-Derived Suppressor Cells via
Targeting Runx1. J Immunol. 2015;195(3):1301-11.
23. Tian X, Tian J, Tang X, et al. Particulate beta-glucan regulates the
immunosuppression of granulocytic myeloid-derived suppressor cells by
inhibiting NFIA expression. Oncoimmunology. 2015;4(9):e1038687.
24. Barrera L, Montes-Servin E, Hernandez-Martinez JM, et al. Levels of
peripheral blood polymorphonuclear myeloid-derived suppressor cells and
selected cytokines are potentially prognostic of disease progression for
patients with non-small cell lung cancer. Cancer Immunol Immunother.
2018;67(9):1393-406.
25. de Goeje PL, Bezemer K, Heuvers ME, et al. Immunoglobulin-like
transcript 3 is expressed by myeloid-derived suppressor cells and
correlates with survival in patients with non-small cell lung cancer.
Oncoimmunology. 2015;4(7):e1014242.
26. Zhang Z, Huang X, Wang E, Huang Y, Yang R. Suppression of
Mll1-Complex by Stat3/Cebpbeta-Induced miR-21a/21b/181b Maintains the
Accumulation, Homeostasis, and Immunosuppressive Function of
Polymorphonuclear Myeloid-Derived Suppressor Cells. J Immunol.
2020;204(12):3400-15.
27. Condamine T, Dominguez GA, Youn JI, et al. Lectin-type oxidized LDL
receptor-1 distinguishes population of human polymorphonuclear
myeloid-derived suppressor cells in cancer patients. Sci Immunol.
2016;1(2).
28. Nan J, Xing YF, Hu B, et al. Endoplasmic reticulum stress induced
LOX-1(+) CD15(+) polymorphonuclear myeloid-derived suppressor cells in
hepatocellular carcinoma. Immunology. 2018;154(1):144-55.
29. Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells
coming of age. Nat Immunol. 2018;19(2):108-19.
30. Singh M, Jadhav HR. Targeting non-small cell lung cancer with
small-molecule EGFR tyrosine kinase inhibitors. Drug Discov Today.
2018;23(3):745-53.
31. Cascone T, Morelli MP, Ciardiello F. Small molecule epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung
cancer. Ann Oncol. 2006;17 Suppl 2:ii46-8.
32. Suresh K, Naidoo J, Lin CT, Danoff S. Immune Checkpoint
Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary
Toxicities. Chest. 2018;154(6):1416-23.
33. Osmani L, Askin F, Gabrielson E, Li QK. Current WHO guidelines and
the critical role of immunohistochemical markers in the
subclassification of non-small cell lung carcinoma (NSCLC): Moving from
targeted therapy to immunotherapy. Semin Cancer Biol. 2018;52(Pt
1):103-9.
34. Dajon M, Iribarren K, Petitprez F, et al. Toll like receptor 7
expressed by malignant cells promotes tumor progression and metastasis
through the recruitment of myeloid derived suppressor cells.
Oncoimmunology. 2019;8(1):e1505174.
35. Li YD, Lamano JB, Lamano JB, et al. Tumor-induced peripheral
immunosuppression promotes brain metastasis in patients with non-small
cell lung cancer. Cancer Immunol Immunother. 2019;68(9):1501-13.
36. Zheng Y, Tian X, Wang T, et al. Long noncoding RNA Pvt1 regulates
the immunosuppression activity of granulocytic myeloid-derived
suppressor cells in tumor-bearing mice. Mol cancer. 2019;18(1):61.
37. Weber R, Fleming V, Hu X, et al. Myeloid-Derived Suppressor Cells
Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors. Front
Immunol. 2018;9:1310.
38. Tian X, Zheng Y, Yin K, et al. LncRNA AK036396 Inhibits Maturation
and Accelerates Immunosuppression of Polymorphonuclear Myeloid-Derived
Suppressor Cells by Enhancing the Stability of Ficolin B. Cancer Immunol
Res. 2020;8(4):565-77.